Metal storage disorders: Wilson disease and hemochromatosis

Medical Clinics of North America

Volumn 98, Issue 1, 2014, Pages 87-102

  Kanwar, Pushpjeet ^a   Kowdley, Kris V ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Copper; Ferritin; Hemochromatosis; Hepcidin; Wilson disease

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; CERULOPLASMIN; DEFERASIROX; FERRITIN; FERROPORTIN; GLUCONIC ACID; HEMOJUVELIN; HEPCIDIN; PENICILLAMINE; SULFATE; TETRATHIOMOLYBDATE AMMONIUM; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; TRIENTINE; ZINC; ZINC DERIVATIVE;

ABDOMINAL PAIN; ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALLERGIC REACTION; AMINOACIDURIA; ARTHROPATHY; ATAXIA; BONE MARROW TOXICITY; CARDIOMYOPATHY; CERULOPLASMIN BLOOD LEVEL; CHROMOSOME 6; COPPER METABOLISM; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSARTHRIA; DYSTONIA; EXON; FATIGUE; FERRITIN BLOOD LEVEL; FEVER; FIBROSIS; GASTROINTESTINAL SYMPTOM; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATOMEGALY; HOMOZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTRANSAMINASEMIA; HYPOGONADISM; HYPOPITUITARISM; INTESTINE CELL; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON STORAGE; JAUNDICE; KIDNEY INJURY; LIBIDO DISORDER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MACROPHAGE; MISSENSE MUTATION; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SKIN DISCOLORATION; SKIN PIGMENTATION; SPASTICITY; SPEECH DISORDER; TREMOR; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

CIRRHOSIS; COPPER; FERRITIN; HEMOCHROMATOSIS; HEPCIDIN; WILSON DISEASE;

BIOPSY; CHELATING AGENTS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEMOCHROMATOSIS; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; PENICILLAMINE; PHLEBOTOMY; PROGNOSIS; TRIENTINE;

EID: 84888024893     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.09.008     Document Type: Review

References (101)

1. Pietrangelo A., Montosi G., Garuti C., et al. Iron-induced oxidant stress in non-parenchymal liver cells: mitochondrial derangement and fibrosis on acutely iron-dosed gerbils and its prevention by silybin. JBioenerg Biomembr 2002, 34(1):67-79.
2. Lloyd D.R., Philips D.H. Oxidative DNA damage mediated by copper(II), iron(II) and nickel(II) fenton reactions: evidence for site-specific mechanisms in the formation of double-strand breaks, 8-hydroxydeoxyguanosine and putative intra-strand cross-links. Mutat Res 1999, 424(1-2):23-36.
3. Eaton J.W., Qian M.W. Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002, 32(9):833-840.
4. Gaetke L.M., Chow C.K. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 2003, 189(1-2):147-163.
5. Krumschnabel G., Manzl C., Berger C., et al. Oxidative stress, mitochondrial permeability transition, and cell death in Cu-exposed trout hepatocytes. Toxicol Appl Pharmacol 2005, 209(1):62-73.
6. Kono S. Aceruloplasminemia. Curr Drug Targets 2012, 13(9):1190-1199.
7. Fleming R.E., Feng Q., Britton R.S. Knockout mouse models of iron homeostasis. Annu Rev Nutr 2011, 21(31):117-137.
8. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010, 139(2):393-408.
9. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007, 46(4):1291-1301.
10. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
11. Feder J.N., Gnirke A., Thomas W., et al. Anovel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
12. Bacon B.R., Olynyk J.K., Brunt E.M., et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999, 130(12):953-962.
13. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., et al. Global prevalence of putative haemochromatosis mutations. JMed Genet 1997, 34(4):275-278.
14. Gochee P.A., Powell L.W., Cullen D.J., et al. Apopulation-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002, 122(3):646-651.
15. Cheng R., Barton J.C., Morrison E.D., et al. Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes. JClin Gastroenterol 2009, 43(6):569-573.
16. EASL clinical practice guidelines for HFE hemochromatosis. JHepatol 2010, 53(1):3-22.
17. Rossi E., Olynyk J.K., Jeffrey G.P. Clinical penetrance of C282Y homozygous HFE hemochromatosis. Expert Rev Hematol 2008, 1(2):205-216.
18. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S79-S86.
19. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. NEngl J Med 2005, 352(17):1769-1778.
20. Bassett M.L., Halliday J.W., Ferris R.A., et al. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984, 87(3):628-633.
21. Beaton M.D., Adams P.C. Treatment of hyperferritinemia. Ann Hepatol 2012, 11(3):294-300.
22. Adams P.C., McLaren C.E., Speechley M., et al. HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 μg/L. Can J Gastroenterol 2013, 27(7):390-392.
23. Adams P.C., Passmore L., Chakrabarti S., et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006, 4(7):918-923.
24. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. NEngl J Med 2008, 358(3):221-230.
25. Allen K.J., Bertalli N.A., Osborne N.J., et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology 2010, 52(3):925-933.
26. Barton J.C., Barton J.C., Acton R.T., et al. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis. Clin Gastroenterol Hepatol 2012, 10(4):412-416.
27. Pietrangelo A. Non-HFE hemochromatosis. Hepatology 2004, 39:21-29.
28. Pietrangelo A., Caleffi A., Corradini E. Non-HFE hepatic iron overload. Semin Liver Dis 2011, 31(3):302-318.
29. Bacon B.R., Adams P.C., Kowdley K.V., et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(1):328-343.
30. St.Pierre T.G., Clarke P.R., Chua-Anusorn W. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105(2):855-861.
31. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363(9406):357-362.
32. Emond M.J., Bronner M.P., Carlson T.H., et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999, 45(3):340-346.
33. Deugnier Y., Turlin B. Pathology of hepatic iron overload. Semin Liver Dis 2011, 31(3):260-271.
34. Adhoute X., Foucher J., Laharie D., et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 2008, 32(2):180-187.
35. Crawford D.H., Murphy T.L., Ramm L.E., et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009, 49(2):418-425.
36. Bomford A., Williams R. Long term results of venesection therapy in idiopathic hemochromatosis. QJ Med 1976, 45(180):611-623.
37. Falize L., Guillygomarc'h A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44(2):472-477.
38. Kelly T.M., Edwards C.Q., Meikle A.W., et al. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984, 101(5):629-632.
39. Cundy T., Butler J., Bomford A., et al. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 1993, 38(6):617-620.
40. Ko C., Siddaiah N., Berger J., et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int 2007, 27(10):1394-1401.
41. Lynch S.R., Skikne B.S., Cook J.D. Food iron absorption in idiopathic hemochromatosis. Blood 1989, 74(6):2187-2193.
42. Phatak P., Brissot P., Wurster M., et al. Aphase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010, 52(5):1671-1679.
43. Rombout-Sestrienkona E., Van Noord P.A., Van Deursen C.T., et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis-a pilot study. Transfus Apher Sci 2007, 36(3):261-267.
44. Bardou-Jacquet E., Philip J., Lorho R., et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 2013, [Epub ahead of print].
45. Yang Q., McDonnell S.M., Khoury M.J., et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998, 129(11):946-953.
46. Niederau C., Fischer R., Sonnenberg A., et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. NEngl J Med 1985, 313(20):1256-1262.
47. Milman N., Pedersen P., á Steig T., et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001, 80(12):737-744.
48. Phatak P.D., Bonkovsky H.L., Kowdley K.V. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008, 149(4):270-272.
49. Adams P.C. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet 1998, 53(3):176-178.
50. Kanwar P., Kowdley K.V. Diagnosis and treatment of hereditary hemochromatosis: an update. Expert Rev Gastroenterol Hepatol 2013, 7(6):517-530.
51. European Association for Study of Liver EASL Clinical Practice Guidelines: Wilson's disease. JHepatol 2012, 56(3):671-685.
52. Coffey A.J., Durkie M., Hague S., et al. Agenetic study of Wilson's disease in the United Kingdom. Brain 2013, 136(Pt 5):1476-1487.
53. Tanzi R.E., Petrukhin K., Chernov I., et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993, 5(4):344-350.
54. Yamaguchi Y., Heiny M.E., Gitlin J.D. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993, 197(1):271-277.
55. Petrukhin K., Fischer S.G., Pirastu M., et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993, 5(4):338-343.
56. Roberts E.A., Schilsky M.L. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47(6):2089-2111.
57. Wilson S.A. Progressive lenticular degeneration: familial nervous disease associated with cirrhosis of liver. Brain 1912, 34:295-509.
58. Gowers W.R. Tetanoid chorea associated with cirrhosis of liver. Dis Nerv System 1888, 2:656.
59. Petrukhin K., Lutsenko S., Chernov I., et al. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994, 3(9):1647-1656.
60. Mercer J.F. The molecular basis of copper-transport diseases. Trends Mol Med 2001, 7(2):64-69.
61. Linder M.C., Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996, 63(5):797S-811S.
62. Mufti A.R., Burstein E., Csomos R.A., et al. XIAP Is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders. Mol Cell 2006, 21(6):775-785.
63. Dabrowska E., Jabłońska-Kaszewska I., Oziebłowski A., et al. Acute haemolytic syndrome and liver failure as the first manifestations of Wilson's disease. Med Sci Monit 2001, 7(Suppl 1):246-251.
64. Rosencrantz R., Schilsky M. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis 2011, 31(3):245-259.
65. Huster D. Wilson disease. Best Pract Res Clin Gastroenterol 2010, 24(5):531-539.
66. Steindl P., Ferenci P., Dienes H.P., et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997, 113(1):212-218.
67. Nicastro E., Ranucci G., Vajro P., et al. Re-evaluation of the diagnostic criteria forWilson disease in children with mild liver disease. Hepatology 2010, 52(6):1948-1956.
68. Ferenci P. Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004, 19(3-4):229-239.
69. Walshe J.M. Diagnostic significance of reduced serum caeruloplasmin concentration in neurological disease. Mov Disord 2005, 20(12):1658-1661.
70. Dhawan A., Taylor R.M., Cheeseman P., et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005, 11(4):441-448.
71. Frommer D.J. Urinary copper excretion and hepatic copper concentrations in liver disease. Digestion 1981, 21(4):169-178.
72. Martins da Costa C., Baldwin D., et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992, 15(4):609-615.
73. Korman J.D., Volenberg I., Balko J., Pediatric and Adult Acute Liver Failure Study Groups, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008, 48(4):1167-1174.
74. Ferenci P., Steindl-Munda P., Vogel W., et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease. Clin Gastroenterol Hepatol 2005, 3(8):811-818.
75. Johncilla M., Mitchell K.A. Pathology of the liver in copper overload. Semin Liver Dis 2011, 31(3):239-244.
76. Milkiewicz P., Saksena S., Hubscher S.G., et al. Wilson's disease with superimposed autoimmune features: report of two cases and review. JGastroenterol Hepatol 2000, 15(5):570-574.
77. Irons R.D., Schenk E.A., Lee J.C. Cytochemical methods for copper. Semiquantitative screening procedure for identification of abnormal copper levels in liver. Arch Pathol Lab Med 1977, 101(6):298-301.
78. Pilloni L., Lecca S., Van Eyken P., et al. Value of histochemical stains for copper in the diagnosis of Wilson's disease. Histopathology 1998, 33(1):28-33.
79. Salaspuro M.P., Pikkarainen P., Sipponen P., et al. Hepatic copper in primary biliary cirrhosis: biliary excretion and response to penicillamine treatment. Gut 1981, 22(11):901-906.
80. Bennett J., Hahn S.H. Clinical molecular diagnosis of Wilson disease. Semin Liver Dis 2011, 31(3):233-238.
81. Chuang L.M., Wu H.P., Jang M.H., et al. High frequency of two mutations in codon 778 in exon 8 of the ATP7B gene in Taiwanese families with Wilson disease. JMed Genet 1996, 33(6):521-523.
82. Nanji M.S., Nguyen V.T., Kawasoe J.H., et al. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997, 60(6):1423-1429.
83. Kim E.K., Yoo O.J., Song K.Y., et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat 1998, 11(4):275-278.
84. Thomas G.R., Forbes J.R., Roberts E.A., et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995, 9(2):210-217.
85. Manolaki N., Nikolopoulou G., Daikos G.L., et al. Wilson disease in children: analysis of 57 cases. JPediatr Gastroenterol Nutr 2009, 48(1):72-77.
86. Ferenci P., Caca K., Loudianos G., et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003, 23(3):139-142.
87. Cumings J.N. The effects of B.A.L. in hepatolenticular degeneration. Brain 1951, 74(1):10-22.
88. Purchase R. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism. Sci Prog 2013, 96(Pt 1):19-32.
89. Scheinberg I.H., Sternlieb I., Schilsky M., et al. Penicillamine may detoxify copper in Wilson's disease. Lancet 1987, 2(8550):95.
90. Aaseth J., Flaten T.P., Andersen O. Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics. Scand J Gastroenterol 2007, 42(6):673-681.
91. Weiss K.H., Thurik F., Gotthardt D.N., et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 2013, 11(8):1028-1035.
92. Taylor R.M., Chen Y., Dhawan A., et al. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. Eur J Pediatr 2009, 168(9):1061-1068.
93. Hall A.C., Young B.W., Bremner I. Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat. JInorg Biochem 1979, 11(1):57-66.
94. Czlonkowska A., Gajda J., Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. JNeurol 1996, 243(3):269-273.
95. Weiss K.H., Gotthardt D.N., Klemm D., et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011, 140(4):1189-1198.
96. Brewer G.J., Askari F., Dick R.B., et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 2009, 154(2):70-77.
97. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003, 60(3):379-385.
98. Brewer G.J., Askari F., Lorincz M.T., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006, 63(4):521-527.
99. Arnon R., Annunziato R., Schilsky M., et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011, 25(1):E52-E60.
100. Thanapirom K., Treeprasertsuk S., Komolmit P., et al. Comparison of long-term outcome of patients with Wilson's disease presenting with acute liver failure versus acute-on-chronic liver failure. JMed Assoc Thai 2013, 96(2):150-156.
101. Nazer H., Ede R.J., Mowat A.P., et al. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986, 27(11):1377-1381.